Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue

Abstract

Gene expression analysis on core biopsy samples is feasible and identifies candidate genes that correlate with pCR to primary chemotherapy. Gene expression in IBC differs significantly from noninflammatory breast cancer.

The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer

“…In addition, it is a prediction tool in determining the benefit of chemotherapy in the adjuvant setting for both node negative and node positive patients [1,18]. However, the ability of this assay to predict the benefit of chemotherapy in the neoadjuvant setting remains controversial [7,14].…”

“…Literature on the topic varies according to the assay used. While some support the use of assays in this capacity [2,7,8,14,16,22,24], others question their validity in predicting response to NCT [20]. Few studies concentrate only on ER+ patients and the ability to predict NCT response in this subset [7,14].…”

The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade

“…For clinical decision-making, the RS is divided into three risk groups: low (<18), intermediate (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31) and high (RS ≥31). Numerous studies have demonstrated that ER-positive breast cancer patients with a low RS have a low risk of recurrence and derive low benefit from chemotherapy, and that ER-positive breast cancer patients with a high RS have a high risk of recurrence but do benefit from chemotherapy [71,[86][87][88][89].…”

Access to Personalized Medicine: Factors Influencing the Use and Value of Gene Expression Profiling in Breast Cancer Treatment

“…One example is gene expression profiling (gep) of breast tumours. Gene expression profiling tests examine expression levels of prognosticallyrelevant genes to establish the likelihood of benefit from chemotherapy and the recurrence risk within 10 years for node-negative, estrogen receptor-positive patients [2][3][4][5][6][7] . The recurrence scores produced by gep tests classify patients into groups with poor or good prognosis: Patients with low scores have a low likelihood of recurrence and will likely derive littleto-no benefit from chemotherapy; those with high scores will have a higher likelihood of recurrence and will likely derive high benefit from adjuvant chemotherapy.…”